A comparison of prostate cancer survival in England, Norway and Sweden: A population-based study

Cancer Epidemiology

Volumn 36, Issue 1, 2012, Pages

  Holmberg, L ^a,b   Robinson, D ^c   Sandin, F ^b   Bray, F ^d,e   Linklater, K M ^c   Klint, A ^f   Lambert, P C ^g,h   Adolfsson, J ⁱ   Hamdy, F C ^j   Catto, J ^k   Moller H ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d CANCER REGISTRY OF NORWAY   (Norway)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k UNIVERSITY OF SHEFFIELD   (United Kingdom)

more..

Author keywords

Cancer registries; Excess mortality; Prostate cancer; Public health practice; Survival analysis

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; DISEASE SEVERITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; PRIORITY JOURNAL; PROSTATE CANCER; SWEDEN; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ENGLAND; HUMANS; MALE; MASS SCREENING; NORWAY; PROSTATIC NEOPLASMS; PUBLIC HEALTH PRACTICE; SURVIVAL RATE; SWEDEN;

EID: 84855837366     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2011.08.001     Document Type: Article

References (22)

1. Berrino F., De Angelis R., Sant M., Rosso S., Lasota M.B., Coebergh J.W., et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007, 8:773-783. the EUROCARE Working group.
2. Collin S.M., Martin R.M., Metcalfe C., Gunnell D., Albertsen P.C., Neal D., et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008, 9:445-452.
3. Sant M., Allemani C., Santaquilani M., Knijn A., Marchesi F., Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009, 45:931-991. EUROCARE Working Group.
4. Abdel-Rahman M., Stockton D., Rachet B., Hakulinen T., Coleman M.P. What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?. Br J Cancer 2009, 101:s115-s124.
5. Møller H., Sandin F., Bray F., Klint å., Linklater K.M., Purushotham A., et al. Breast cancer survival in England, Norway and Sweden: a population-based comparison. Int J Cancer 2010, 127:2630-2638.
6. Holmberg L., Sandin F., Bray F., Richards M., Spicer J., Lambe M., et al. National comparisons of lung cancer survival in England, Norway and Sweden 2001-2004: differences occur early in follow-up. Thorax 2010, 65:436-441.
7. Morris E., Sandin F., Lambert P.C., Bray F., Klint å., Linklater K., et al. A population-based comparison of the survival of colorectal cancer patients in England, Norway and Sweden between 1996 and 2004. Gut 2011, 10.1136/gut.2010.229575.
8. Adolfsson J., Garmo H., Varenhorst E., Ahlgren G., Ahlstrand C., Andrén O., et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007, 41:456-477.
9. Ederer F., Axtell L.M., Cutler S.J. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961, 6:101-121.
10. Brenner H., Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996, 78:2004-2010.
11. Corazziari I., Quinn M., Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004, 40:2307-2316.
12. Lambert P.C., Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009, 9:265-290.
13. Statacorp Stata statistical software: release 9 2005, Statacorp, College Station.
14. Bray F., Klint å., Gislum M., Hakulinen T., Engholm G., Tryggvadóttir L., et al. Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964-2003 followed up until the end of 2006. Acta Oncol 2010, 49:644-654.
15. Melia J., Moss S., Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int. 2004, 94:51-56.
16. Mokete M., Shackley D.C., Betts C.D., O'Flynn K.J., Clarke N.W. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK. BJU Int. 2005, 97:266-269.
17. Telesca D., Etzioni R., Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008, 64:10-19.
18. Draisma G., Boer R., Otto S.J., van der Cruijsen I.W., Damhuis R.A., Schröder F.H., et al. Lead times and overdetection due to prostate-specific antigen testing: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 2003, 95:868-878.
19. Lyratzolpoulus G., Barbiere J.M., Greenberg D.C., Wright K.A., Neal D.E. Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey. BMJ 2010, 340:c1928.
20. Thomson C.S., Forman D. Cancer survival in England and the influence of early diagnosis: what can we learn from the EUROCARE results?. Br J Cancer 2009.
21. Nanda A., Chen M.H., Braccioforte M.H., Moran B.J., D'Amico A.V. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009, 302:866-873.
22. Welch H.G., Albertsen P.C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009, 101:1325-1329.